Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
NCT07868835 is registered in ClinicalTrials.gov with Viking Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
- Lead sponsor
- Viking Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 15, 2026
- Completion date
- August 31, 2028
- Enrollment
- 560 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.